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The role of the induction of oxidative stress as themechanism of action of many antitumor drugs is acquiring an increasing interest.
In such cases, the antitumor therapy success may be conditioned by the antioxidants present in our own body, which can be
synthesized de novo (endogenous) or incorporated through the diet and nutritional supplements (exogenous). In this paper, we
have reviewed different aspects of antioxidants, including their classification, natural sources, importance in diet, consumption
of nutritional supplements, and the impact of antioxidants on health. Moreover, we have focused especially on the study of the
interaction between antioxidants and antitumor therapy, considering both radiotherapy and chemotherapy. In this regard, we found
that the convenience of administration of antioxidants during cancer treatment still remains a very controversial issue. In general
terms, antioxidants could promote or suppress the effectiveness of antitumor treatment and even protect healthy tissues against
damage induced by oxidative stress. The effects may depend on many factors discussed in the paper. These factors should be taken
into consideration in order to achieve precise nutritional recommendations for patients. The evidence at the moment suggests
that the supplementation or restriction of exogenous antioxidants during cancer treatment, as appropriate, could contribute to
improving its efficiency.
1. Introduction
The first definition of antioxidant was proposed by Halli-
well et al. in 1989 as “any substance that, present in low
concentrations compared to oxidizable substrates (carbohy-
drates, lipids, proteins or nucleic acids), significantly delays
or inhibits the oxidation of the mentioned substrates” [1].
Later, other definitions of antioxidant were proposed, such as
“any substance that prevents, delays or eliminates oxidative
damage of a target molecule” [2] or “any substance that can
eliminate reactive oxygen species directly or indirectly, acting
as a regulator of the antioxidant defense, or inhibiting the
production of those species” [3].
Reactive oxygen species (ROS) are a group of molecules
produced by some metabolic processes, due to the action of
oxidases in themitochondria or other cellular compartments.
ROS have high reactivity because they possess unpaired
electrons that can interact with oxidizable substrates through
redox reactions. The main ROS involved in the biological
systems are superoxide anion, hydroxyl radical, hydroperoxyl
and peroxyl radical, nitric oxide, and other species such as
hydrogen peroxide, singlet oxygen, and hypochlorous acid
[4, 5]. However, there are other reactive molecules derived
from the reaction of ROS with nitric oxide (reactive nitrogen
species, RNS) or thiols (reactive sulfur species, RSS) [6]
(Figure 1).
The balance between oxidants and antioxidants (redox
balance) is essential in maintaining a healthy cellular
microenvironment. The generation of oxidative stress is
caused by an alteration in the balance between ROS pro-
duction and the efficiency of the cell antioxidant defense
system. Cells and tissues are continuously being exposed to
free radicals derived from themetabolism or external factors,
such as pollution, microbes, allergens, radiation, cigarette
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Figure 1: Oxygen reactive species (ROS) and derivatives. ROS
includes superoxide anion, hydroxyl radical, singlet oxygen,
hydroperoxyl radical, peroxyl radical, hydrogen peroxide, and
hypochlorous acid. There are other reactive species which result
from the reaction between ROS and nitric oxide (reactive nitrogen
species, RNS), or with thiols (reactive sulfur species, RSS) [4–6].
smoke, and pesticides [7]. However, ROS can play a dual
role, acting as beneficial or harmful factors [8]. On the one
hand, the increase in ROS production generates oxidative
stress, a damaging process that can alter cell structures and
influences the expression of genes related to accelerated cell
aging [9]. Nevertheless, ROS derived from the mitochondrial
respiratory chain, at low or moderate concentrations, partic-
ipate in physiological functions such as in the defense against
infections and in the maintenance of redox balance [9, 10].
Cells have several mechanisms to transform and elimi-
nate ROS to avoid their harmful effects.The synergistic action
of both antioxidant proteins and enzymes and exogenous
antioxidants neutralize free radicals andmodulate cell signal-
ing [11]. In fact, numerous studies suggest that antioxidants
exert a protective effect against radiation and also prevent
the development of many diseases such as cancer, atheroscle-
rosis, stroke, rheumatoid arthritis, neurodegeneration, and
diabetes [12, 13].
2. The Antioxidant Defense
The natural antioxidant defense is composed of endoge-
nous antioxidants, which are enzymatic and nonenzymatic
antioxidants produced by our own body, and exogenous
antioxidants, which can be incorporated through the diet or
nutritional supplements [14]. Furthermore, there is another
group that comprises synthetic antioxidants widely used in
the food industry, such as butylated hydroxyanisole (BHA),
butylated hydroxytoluene (BHT), propyl gallate (PG), and
tert-butylhydroquinone (TBHQ). Several in vivo studies car-
ried out in the 80s and the 90s reported some health risks
associated with the consumption of synthetic antioxidants
[15]. However, this is a controversial issue. A trial conducted
in 1993 suggested that the toxic effects produced by BHA and
BHT occur only at high doses in long-term treatments [16].
Another study found that the usual intake of BHA and BHT
at low doses is not associated with stomach cancer risk [17].
More recently, the European Food Safety Authority (EFSA)
studied in depth all the contradictory published data and
established that the acceptable daily intakes of 0,25mg/kg/day
for BHA and 1,0mg/kg/day for BHT are safe for adults and
children [18].
Antioxidants can be classified into three lines of defense
according to theirmechanismof action.Thefirst line includes
antioxidants that prevent the formation of new free radicals.
It is a very heterogeneous group which includes enzymes
such as superoxide dismutase (SOD), catalase (CAT), and
glutathione peroxidase (GPX); proteins that bindmetals such
as ferritin and ceruloplasmin; and minerals such as Se, Cu,
and Zn. The second group of antioxidants is responsible for
capturing free radicals, and thus they prevent oxidative chain
reactions. This group is formed by the glutathione enzyme,
albumin, vitamins C and E, carotenoids, and flavonoids. The
third line of defense includes antioxidant enzymes that repair
the damage caused by free radicals to biomolecules, such
as lipases, proteases, DNA repair enzymes, transferases, and
methionine-sulfoxide reductases [19–21]. Most exogenous
antioxidants are produced by vegetables. Therefore, they are
often called phytochemicals, although this is a concept which
refers to any chemical compound derived from plants [22]
(Figure 2).
3. Classification of Exogenous Antioxidants
Exogenous antioxidants constitute a very large and diverse
group ofmolecules in terms of chemical structure and biolog-
ical properties [23, 24]. Due to the abundance and diversity
of members, this group can be divided into three subgroups:
polyphenols, vitamins and derivatives, and antioxidant min-
erals [18].
Polyphenols are the most abundant natural antioxidants.
The twomain types of polyphenols are flavonoids and pheno-
lic acids. For its part, flavonoids can be classified into several
groups: flavonols, flavanones, flavones, catechins, antho-
cyanins, and isoflavones. Polyphenols are usually secondary
metabolites involved in the defense against UV radiation or
pathogens [25]. They are found in all plant products such as
fruits, vegetables, juices, tea, and wine, and they contribute
to their color, taste, smell, and oxidative stability [26]. Numer-
ous epidemiological studies in the late twentieth century
have suggested that polyphenols confer some protection
against the development of prevalent diseases, including
diabetes, infections, cancer, cardiovascular diseases, asthma,
and osteoporosis [23, 27, 28].
Within the family of vitamins and derivatives, we want to
highlight vitamins C, E, and K and carotenoids. Carotenoids
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Figure 2: The antioxidant defense. The human antioxidant defense is composed of exogenous and endogenous antioxidants that can be
classified into three different lines regarding their mechanism of action.The first line prevents the formation of new free radicals and includes
SOD, CAT, GPX, ferritin, ceruloplasmin, Se, Cu, and Zn. The second line captures free radicals to prevent the oxidative chain reactions and
includes gluthatione, vitamins C and E, carotenoids, and flavonoids.The third line repairs the damage caused to biomolecules by free radicals
and includes DNA repair enzymes, lipases, proteases, transferases, and methionine-sulfoxide reductases [19–21].
are a group of pigments present inmany fruits and vegetables.
There are more than 600 types, but only a few of them
have demonstrated biological properties, as is the case of
𝛽-carotene and lycopene. 𝛽-Carotene is the most studied
antioxidants for the prevention of diseases [29]. A product of
the hepatic catabolism of 𝛽-carotene is vitamin A or retinol,
which has beneficial effects on the skin, eyes, and internal
organs, and that has the ability to combine and neutralize per-
oxyl radicals before they produce lipid peroxidation [30, 31].
Vitamin C or ascorbic acid is known by its electron-
donating ability, thanks towhich it prevents the accumulation
of oxidizing agents and free radicals. It is especially efficient
in eliminating superoxide anion radicals, hydrogen peroxide,
hydroxyl, singlet oxygen, and RNS [32, 33]. Vitamin E
family includes tocotrienols and tocopherols.They are highly
lipophilic molecules that exert an antioxidant action due to
their ability to join biological membranes, stabilizing and
protecting them against lipid peroxidation [29]. Vitamin K
is also lipophilic and it is involved in the blood clotting
process. There are two known natural isoforms of vitamin
K. K
1
is present in green plants and is called phylloquinone,
while K
2
types are produced by bacteria of the intestinal
flora and are called menaquinones. Although vitamin K is
not considered a classic antioxidant, various studies have
demonstrated its ability to slow the depletion of glutathione
caused by oxidative stress [34].
Within the group of antioxidant minerals, selenium has
a special importance because it is a cofactor of antioxidant
enzymes such as GPX and thioredoxin reductase, among
others [35]. Its role as part of the superoxide dismutase
(SOD) and its capacity of inhibiting the NADPG oxidases
that catalyze the transformation of oxygen into singlet oxygen
radical are also relevant [18]. Similarly, it has been found that
zinc can prevent lipid peroxidation and therefore protect cell
membranes [36–38].
Apart from the antioxidants mentioned above, in recent
years, the importance attributed to melatonin and N-
acetylcysteine (NAC) as antioxidants has risen. Melatonin
is the main product produced by the pineal gland. It exerts
antioxidant activity both directly and indirectly, and it also
has anti-inflammatory properties. Melatonin can directly
eliminate free radicals such as hydroxyl radical, oxygen
singlet, hydrogen peroxide, and peroxynitrite, and indirectly
it induces the production of antioxidant enzymes, including
GPX, glutathione reductase, Glucose 6P-DH, and SOD.
Moreover, unlike classic antioxidants, melatonin does not
produce a dose-dependent prooxidant effect, and it is able
to cross the blood brain barrier [39]. For its part, NAC has
mucolytic properties, it is the precursor of L-cysteine, and it
is able to eliminate ROS and restore intracellular glutathione
levels. In addition, recent studies indicate that NAC could
cross the blood brain barrier, although depending on the dose
andmethod of administration. Bothmelatonin andNAC also
stand out for their low toxicity [40].
4. Sources of Exogenous Antioxidants and Diet
Numerous studies have focused on determining the antiox-
idant content of foods, which conclude that the food with
more antioxidant is derived from the plant kingdom (fruits,
vegetables, and cereals), while meat and fish are poor in
antioxidants. Comparing the group of meat and meat prod-
ucts, with plant foods such as fruits, nuts, cocoa, and berries,
the latter are 5- to 33-fold richer in antioxidants than the
former [41]. Therefore, diets mainly composed of animal
source foods may not provide sufficient antioxidants, which
could increase the oxidation of biomolecules and cell damage
[42]. Nevertheless, proteins and hydrolysates derived from
milk and eggs have shown some antioxidant activity [43].
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Table 1: Classification of biologically relevant exogenous antioxidants and their natural sources [13, 41].
Exogenous antioxidants Sources
Vitamins and derivatives
Vitamin C Berries, citrus fruits, some vegetables (peppers, cabbage), pulses, and some herbs and spices
Vitamin E Seeds, vegetable oils, peanuts, nuts, and some fruits
Vitamin K Green leafy vegetables, some herbs and spices
Carotenoids
𝛽-Carotene Many vegetables (spinach, carrots, pumpkins, and red pepper) and fruits (mango, apricots, and peaches)
Lycopene Tomatoes, ketchup, and watermelon
Polyphenols
Flavonoids
Quercetin Fruits (apples, citrus), onions, parsley tea, red wine, and green leafy vegetables
Catechins Green tea, cocoa, and berries
Proanthocyanidins Many fruits and vegetables, nuts, seeds, cocoa, and some medicinal herbs
Genistein and daidzein Soy
Hesperetin Citrus fruits
Resveratrol Red grapes, red wine, peanuts, and berries
Phenolic acids
Caffeic and chlorogenic acids Coffee
Ferulic acid Cereals, seeds, citrus fruits, and some vegetables
As stated above, polyphenols are the most abundant
group of natural antioxidants. One of them, resveratrol,
stands out for its antitumor properties, an aspect that will be
discussed later in this paper.Thismolecule can be synthesized
by a large number of plants, in which it seems to protect
against different forms of stress such as heat, insects, bacteria,
and fungi.
Resveratrol is present in common foods like red grapes
and wine, peanuts, and berries [44]. Other important dietary
polyphenols are catechins, present in green tea and some
fruits [45, 46]; proanthocyanidins, present inmany fruits and
vegetables, nuts, and seeds [47]; quercetin found in fruits,
vegetables, tea, and wine [48, 49]; genistein and daidzein in
soy [50]; the phenolic acids in many fruits and vegetables;
the hesperetin present in some citrus [51]; the chlorogenic
and caffeic acids which abound in coffee [52]; and ferulic
acid, found in cereals, citrus fruits, and some vegetables [53].
Cereals, pulses, and nuts also have important polyphenol
content [41, 54] (Table 1).
Tea and coffee are very important sources of antioxidants
for humans. They are rich in polyphenols and also the two
most consumed beverages on the planet after water [54, 55].
Cocoa has a high content of flavanols and procyanidins,
and in vitro studies have shown that it possesses anti-
inflammatory, antiallergic, antiviral, and even antitumor
properties [56–58].
Traditional medicinal plants are especially rich in antiox-
idants, for example, the sap from the trunk of Croton lechleri
in Peru, known as “sangre de grado” or blood of dragon.
This sap has been used for a long time by the Indians of
South America to heal wounds, demonstrating antifungal,
antiseptic, antiviral, and antihemorrhagic properties. Itsmain
components are proanthocyanidins that have the ability
to accelerate the healing of stomach ulcers and to induce
apoptosis in some tumor cells [59, 60]. Another interesting
plant is Triphala, from India, which seems to possess anti-
inflammatory, antibacterial, and anticancer properties [61].
Although herbs and spices constitute only a small per-
centage of the daily food intake, they can be an important
source of exogenous antioxidants, especially in cultures
where spices are regularly used for cooking [22]. Curcumin is
extracted from the plant Curcuma longa, and it is commonly
used in India. Curcumin has shown anti-inflammatory,
antimicrobial, cardioprotective, and neuroprotective proper-
ties, among others [62–64]. Recently, it has been found that its
mechanism of action involves the expression of antioxidant
enzymes such as glutathione transferases, glutathione reduc-
tase, and catalase in liver, kidney, and small intestine [64–66].
The content of vitamin C and tocopherols in rosemary (Ros-
marinus officinalis) [67], sage (Salvia officinalis) [68], and cat’s
claw (Uncaria tomentosa) [69] extracts, which are currently
used as alternatives sources to synthetic antioxidants in the
food industry, has to be highlighted.
Vegetables, fruits, olive oil, and red wine are basic
ingredients of the Mediterranean diet. These foods provide
a wide variety of antioxidants such as vitamins C and E,
polyphenols, and carotenoids [13]. In fact, beneficial effects
of the Mediterranean diet, regarding the prevention of car-
diovascular diseases and the improvement in cognitive status,
have been reported [70, 71].
It is important to note that the antioxidant content of
natural products and foods can vary formany reasons, such as
the environmental and climatic conditions of growth, storage
conditions, and the existence of genetically different varieties
[72]. Similarly, the antioxidant content may be substantially
modified after processing or cooking. This is the case of
berries, which are an important source of flavonoids like
tannins, stilbenes, lignans, and phenolic acids. However,
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during the transformation process of berries into jams and
syrup, the content of phenols is reduced up to half of
the original amount [72, 73]. However, in other cases, the
processing liberates elements included in the food matrix,
leading to an increase in the content of certain antioxidants.
An example is the tomatoes, since their content in lycopene
is available only when they are processed by heat [74, 75].
5. Antioxidant Supplementation
Although cells possess a large repertoire of enzymes and
antioxidants, sometimes these agents are insufficient to nor-
malize the redox state produced by an intense oxidative stress
[76]. In these cases, exogenous antioxidant supplements may
be required to restore the cell redox homeostasis [77].
A nutritional or dietary supplement can be defined
as any product directed to improve human nutrition and
which must contain at least one dietary ingredient. The
classic mode of administration of nutritional supplements is
orally, in all physical forms, liquid, powder, tablets, capsules,
drops, and ampoules. However, in some experimental trials,
supplements can be administered by other routes, such as
parenteral [78].
The composition of the supplements is very variable.They
can contain only vitamins (vitamins C, B and/or multivita-
mins), only minerals (selenium, zinc, iron, or multimineral),
or a combination of vitamins andminerals (multivitamin and
multimineral;MVM).Other supplements aremixtures of oils
and vitamins or minerals, or plant extracts (ginseng, fiber).
Both in Europe and in the United States, the most consumed
supplements areMVM, and themost consumed antioxidants
are vitamins C, E, D, and A [79, 80]. Additionally, vitamin
E is usually added as an antioxidant to preserve different
formulations of supplements.
It has been suggested that antioxidant supplementation
may protect against oxidative stress associated with the devel-
opment of certain diseases or that it may reverse the oxidative
stress produced during their course. This knowledge has
contributed to the fact that the consumption of antioxidant
supplements had become an increasingly common practice
in the population for the maintenance of physical andmental
health [81]. However, the reasons that justify antioxidant
supplements consumption vary according to people’s age and
sex. Usually, older people take them to treat ailments or
health problems, while young people consume supplements
to achieve higher levels of body energy and to strengthen
the immune system. Moreover, women are more likely to use
supplements to prevent bone and colon diseases, while men
take them to prevent cardiovascular diseases [79, 80].
AHRQ (Agency for Healthcare Research and Quality) in
USA conducted a review of all the articles published between
1996 and 2006 related to the preventive effect of MVM
supplements on the development of chronic disease [82].The
nutrients considered in the supplements were vitamins D, E,
and A, folic acid, calcium, iron, selenium, and 𝛽-carotene;
the diseases were hepatitis, AIDS, rheumatoid arthritis, renal
failure, dementia, Parkinson, type II diabetes, cancer, and
some ocular diseases (cataracts and macular degeneration),
among others. Interestingly, they did not find significant
benefits of antioxidant intake for prevention of these diseases
and very limited benefit of MVM supplements on primary
cancer prevention. The only significant relation found was
a reduction in the progression of macular degeneration in
smokers who had taken zinc-based supplements.
However, several clinical trials demonstrated that some
antioxidant supplements improve the recovery of patients
who suffer diseases associated with an excessive production
of ROS, for example, premature infants with bronchopul-
monary dysplasia (vitamins A, E, recombinant human SOD,
Zn, and Se), necrotizing enterocolitis (glutamine, arginine,
and human recombinant SOD), periventricular leukomalacia
(vitamin E, lactoferrin, and cysteine), or retinopathy (resver-
atrol, caffeic acid, and epicatechin) [83], and also in cases
of idiopathic male infertility (vitamins C, E, coenzyme Q10,
glutathione, and selenium) [84]. According to these results, in
an experimental assay it was observed that pomegranate juice
and resveratrol, orally administered tomicemothers, provide
significant protection to their newborn pups against the
brain damage caused by hypoxic-ischemic insult. Similarly,
supplementation with omega-3 fatty acids could reduce brain
damage from rodents, even five weeks after hypoxic-ischemic
insult [85, 86].
We have found numerous studies focused specifically on
the effect of antioxidant supplementation on cancer and its
treatment. These themes will be discussed in the next two
sections of this paper.
6. Role of Antioxidants in Human Health
Attending to the literature, we believe that antioxidants have
impact on health. The questions to be answered are what
is the right antioxidant for each particular physiological or
pathological condition? And how the antioxidants must be
taken, through food or as nutritional supplements? [87].
Many oxidative substances that penetrate into our body
through ingestion, inhalation, or skin can be harmful. These
substances can generate free radicals that are being accumu-
lated. This accumulation can cause damage and even death
due to the biological consequences, whether the antioxidant
defense is sufficient or not. Currently, the main causes for
reducing the plasma level of antioxidants are smoking and
chronic alcoholism [21]. In the skin, for example, there is
an antioxidant defense against UV radiation. It is formed by
melanin and antioxidant enzymes but also by food antiox-
idants. This defense prevents swelling, wrinkling, and skin
cancer. For that reason, some authors recommend the use of
skin protective creams together with antioxidants orally or by
topical application, to avoid the damaging effect of sun [88].
The benefit of antioxidant uptake has been demonstrated
in the course of some diseases and certain conditions
as diabetes, asthma, hemodialysis, thalassemia, rheumatoid
arthritis, systemic attack, postmenopause, schizophrenia,
depression, and leukemia [89, 90] (Figure 3).
The consumption of polyphenols has been associated
with the prevention of the development of atheromatous
lesions [91], the reduction of the size of such lesions in vivo
[92, 93], and the inhibition of platelet aggregation in vitro
[94] and in vivo [95]. In addition, polyphenols seem to reduce
6 Oxidative Medicine and Cellular Longevity
Antioxidants
Diabetes 
Counteract the increase of 
oxidative stress and the 
decrease of the antioxidant 
defense during the disease
Aging
Protect skin from oxidative 
stress caused by U.V. radiation 
Cardiovascular diseases
Reduce the size of atheromatous lesions, 




Protect brain avoiding the 
damage caused by oxidative stress
Cancer
Prevent DNA damage and reduce the
adverse effects caused by oxidative stress
Others
Eye-related disorders, asthma, 
postmenopause,
Reduce oxidative stress 
infections, and so forth.
Figure 3: Influence of antioxidants on human health. Antioxidants can influence many aspects of human health such as diabetes, aging,
cardiovascular and neurodegenerative diseases, cancer, and other illnesses. Antioxidants produce several beneficial effects, promoting a
healthy status, reducing the oxidative stress caused by ROS [89, 90].
the oxidation of LDL, a process that may be responsible
for atherosclerosis development. For its part, tea catechins
inhibit proliferation and invasiveness of smooth muscle cells
in the artery walls of experimental animals. This effect could
contribute to reducing the formation of atheromatous lesions.
However, this effect has not been fully clarified in humans
[91].
Oxidative stress and the damage it causes in the brain
are involved in the pathophysiology of highly prevalent
neurodegenerative diseases. Several studies suggested that
the consumption of foods rich in polyphenols can prevent the
development of these diseases [96, 97]. Green tea provides
protection against Parkinson [10], and daily consumption
of wine has been linked to a lower incidence of dementia
and Alzheimer [98]. In fact, it has been shown that dietary
polyphenols act against hydrogen peroxide, being more
effective than vitamins [99]. Similarly, the consumption of
fruit and vegetable juices may also play an important role in
delaying the development of neurodegenerative disease [100].
In the area of our interest, that is, cancer, antioxidants are
acquiring great importance. It is believed that antioxidants
can prevent the development of cancer due to their effects on
cell cycle regulation, inflammation, the inhibition of tumor
cell proliferation and invasiveness, the induction of apoptosis,
and the stimulation of the detoxifying enzyme activity [29,
101]. The antitumor effect of some polyphenols, such as
catechins, isoflavones, lignans, flavanones, resveratrol, ellagic
acid, quercetin, and curcumin, has been extensively studied.
It has been found that these compounds are able to reduce
tumor growth through various action mechanisms, in differ-
ent locations such as mouth, stomach, liver, lung, duodenum,
colon, mammary gland, and skin [102–104].
One important antioxidant is resveratrol, since it has
demonstrated both in vivo and in vitro ability to slow down
tumor progression in experimental models of lung, skin,
breast, and colon cancer, it interferes with the inflammatory
mechanisms, and it has antiangiogenic and antimetastatic
properties [104–106]. These findings, coupled with the fact
that high doses of oral resveratrol seem to be nontoxic, make
resveratrol a promising antioxidant for cancer therapy [107].
Regarding the prevention of cancer, there are numerous
studies that often provide conflicting conclusions. As an
example, a systematic review of lung cancer concluded that
there was evidence to recommend supplements of vitamins
A, C, and E and selenium, both individually and in combi-
nation, to prevent lung cancer. This study also could indicate
that the intake of 𝛽-carotene supplements may be associated
with a small increase in the incidence and mortality from
cancer in active and passive smokers [108]. This unfavorable
aspect of the intake of supplements confirms the results of
earlier trials as “The 𝛼-Tocopherol and 𝛽-Carotene Trial”
(ATBC) and “The Carotene and Retinol Efficacy Trial”
(CARET), which also were conducted with smokers. Both
studies had to be suspended after observing an increase in
the incidence of lung cancer besides an increased mortality
due to this cancer [14, 109].
However, some studies have shown reported benefits of
consuming antioxidant supplements, such as the trial made
by Lappe et al., which showed that supplementation with
vitaminD and calcium could reduce the overall risk of cancer
in postmenopausal women older than 55 years [110]. In this
regard, there is an outstanding study of primary prevention,
conducted in large-scale, named NIT (Linxian General Pop-
ulationNutrition Intervention Trial), which initially involved
29.584 adults of both sexes. This trial evaluated the effect
of the intake of supplements of 𝛽-carotene, selenium, and
vitamins E and D, over 10 years in the Chinese town of
Linxian. Interestingly, they found a decrease in mortality
caused by cancer, especially in stomach cancer. Similarly,
it was found that the treatment with supplements tends to
be more beneficial in young people. So, the individual’s age
appears to play a crucial role in the effects obtained [111].
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There are some trials that suggest that flavonoids may
have a preventive role against colorectal cancer recurrence.
One of these studies involved a population of 87 patients
who had underwent colon resection or polypectomy and
took a supplement composed of a mixture of apigenin and
epigallocatechin 3-gallate (EGCG). After 3-4 years of treat-
ment and monitoring by colonoscopy, the results with this
long-term treatment appeared to decrease the recurrence of
colon cancer in patients with resected colon [112]. Likewise, a
similar study found that a high intake of flavonoids was asso-
ciated with a reduced risk of advanced adenoma recurrence
[113]. Among flavonoids, the mentioned EGCG is the major
green tea catechin that has been studied more intensively in
recent years. Some studies have shown that the intake of this
compound can inhibit the disease progression in lung, cervix,
breast, stomach, liver, and colon cancer [114]. In addition,
numerous clinical trials have been conducted to study the
effects of this catechin. One of them involved 8000 patients
with stage I or II of breast cancer. Its results revealed that
daily consumption of green tea could reduce the recurrence of
breast cancer and increase the disease-free survival [114, 115].
The SU.VI.MAX trial is a valuable study that showed
controversial results. This study took place in France and
included 7876 women aged between 35 and 60 years and
5141 men aged between 45 and 60 years. They were given
daily oral supplements in capsules including 6mg𝛽-carotene,
120mg vitamin C, 30mg 𝛼-tocopherol, 100 𝜇g selenium, and
20mg zinc, individualized or mixed form [140]. The effects
of each supplement were evaluated separately and combined.
Individual selenium supplementation was associated with
some protection against the development of cancer in general
in both sexes. This fact has been confirmed by other studies
[141]. However, combined therapy consisting of vitamins C
and E, 𝛽-carotene, selenium, and zinc appeared to reduce the
incidence of any type of cancer in men but not in women.
Researchers attributed this result to the fact that the group
of women was younger and less smokers and enjoyed better
health than men. Furthermore, previous to the trial, blood
tests showed that female samples were higher in vitamin C
and 𝛽-carotene than male samples [140].
Interestingly, supplementation reduced the risk of
prostate cancer in 94% of men, while the remaining 6%,
who had a higher level of prostate-specific antigen (PSA) in
serum, showed an increased risk of developing the disease.
It is believed that this beneficial effect would be provided
by selenium. This antioxidant mineral may be effective in
healthy people or in early stages of the disease, but not in
later stages, as in the case of prostate cancer associated with
elevated levels of PSA [14, 142]. The intake of selenium as a
supplement has shown no effect on the incidence of prostate
cancer in patients at high risk for the disease, either with
elevated PSA levels or under suspicion of cancer after a
digital rectal examination [143]. However, selenium through
diet has been associated with a lower risk of pancreatic cancer
(up to 20 𝜇gr/day), although this effect seems to disappear
if there is an additional intake of MVM supplements that
increase the levels of selenium [144].
There is evidence to suggest that the intake of tea and
coffee antioxidants, especially vitamin E in form of gamma-
tocopherol, would provide some protection against the devel-
opment of prostate cancer [145, 146]. Similarly, in a clinical
trial conducted in Canada, a group of men suffering prostate
neoplasia were given daily supplements compound of soy
proteins (40 g), vitamin E (800 IU), and selenium (200mg)
for 3 years. It was observed that this supplement appeared
to reduce the incidence of prostate cancer [147]. Also, the
effect other minerals, such as zinc, could produce on this
disease was assessed. Both in in vitro and in vivo studies,
the ability of zinc was found to inhibit the proliferation of
prostate tumor cells [148, 149]. Other studies have provided
more data about the role of zinc in the course of the disease
[150]. Furthermore, the epidemiological study conducted by
Leitzmann et al. [151] showed that a high intake of zinc
supplementation (>100mg/day) would increase the risk of
prostate cancer, while, according toHo, the dietary deficiency
of this mineral would increase the production of oxidative
stress, and, thus, it would increase cell damage both in vitro
and in vivo [152].
A study conducted in Bangladesh, which began in 2006,
was to prove the administration of vitamin E and selenium
for five years, individually and in combination, to offset
the adverse effects of exposure to arsenic suffered by the
population The aim was to improve the skin lesions and
reduce the incidence of skin cancer caused by arsenic toxicity.
However, they found that although the treatment improved
the evolution of lesions, there was an increase in mortality
and skin dysplasia in the supplemented patients [153]. Sim-
ilarly, recent in vivo studies conducted in mice have shown
that the intake of supplements with vitamin E and NAC led
to greater progression of lung cancer [154].
7. Antitumor Therapy, Oxidative Stress, and
Interactions with Antioxidants
Some evidence suggests that cancer cells have a higher level
of oxidative stress compared to normal cells. This stress
is associated with an increased production of ROS and
some changes in the metabolic activity related to oncogenic
transformation [155]. Therefore, tumor cells may be more
sensitive to drugs that generate big amounts of ROS, or drugs
that damage the ROS scavenging capacity of cells, leading
these cells to death by apoptosis [156]. Apoptosis is conducted
by proteases called caspases, of which there are two main
waterfalls, and acts to produce cellular DNA damage and
disruption of microtubules [157].
In a multifactorial disease as cancer, an important aspect
to consider is the relation between antioxidants and gene
expression. Tumor cells show elevated levels of ROS, which
may alter prooncogenic signaling pathways that contribute
to the malignant phenotype of cells. In this sense, some of
the most studied routes are Nrf2 and p53. Nrf2 belongs to
an important signaling pathway that controls the expression
of genes involved in the neutralization of oxidant agents
[158], and the p53 pathway protects the DNA from the
oxidation induced by ROS [159, 160]. Many signaling path-
ways associated with carcinogenesis are related directly or
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indirectly to ROSmetabolism.Thus, these pathwaysmay also
be influenced by the presence of antioxidants [161].
Increased ROS during cancer development makes tumor
cells become highly dependent on antioxidant agents. For this
reason, low concentrations of free radicals due to an excessive
administration of antioxidantsmay promote the proliferation
of harmful cells in the neoplastic state, promoting the devel-
opment of cancer rather than interrupting it [101]. Another
aspect to consider is that the intense generation of ROS
in tumor cells could damage DNA, promoting the genetic
instability and the development of drug resistance. However,
it seems interesting to develop new therapeutic strategies to
eliminate tumor cells usingROS-mediatedmechanisms [155].
Radiation therapy is based on the ability of the ionizing
radiation to kill cells. This therapy involves the generation
of ROS, including hydroxyl radicals, superoxide anion, and
other organic radicals, and also producing lipid peroxidation
[126, 162]. In the presence of oxygen, these radicals cause
increased formation of other ROS such as peroxides [163].
Therefore, radiation adverse effects would be influenced by
these increased radicals, affecting the cellular antioxidant
status [164]. In the trial conducted by Bairati et al. with head
and neck cancer patients, whowere treated with radiotherapy
and supplemented with high doses of vitamin C and E,
they seemed to improve the adverse effects, but also a loss
of effectiveness of the treatment was observed, even an
increased mortality in patients who received the treatment
with antioxidants [116, 117]. There are several studies that
have linked the consumption of these vitaminswith improved
adverse effects during both chemotherapy and radiotherapy
[165–167]. However, other trials showed that the intake of
vitamins does not improve the side effects and could even
reduce the efficacy of the treatment [168] (Table 2(a)).
Moreover, some studies have reported that curcumin
could have synergistic effect with radiotherapy, whether
administered separately or in combination [136, 169]. It was
observed that, using cell lines of head and neck squamous
cell carcinoma (HNSCC), SCC1, SCC-9, A431, and KB, the
combination of curcumin and radiation resulted in a greater
antitumor effect [124]. The role of curcumin as a radiosensi-
tizer has been supported by the results from other studies,
such as the cases of prostate [170], breast [171], colorectal
[172], and ovarian tumors [173], among others [62, 174].
Another promising radiosensitizer is EGCG. This cate-
chin has shown synergistic effects with radiation on radiore-
sistant glioblastoma multiforme, multiple myeloma (IM-9),
leukemia (K-562), and cancer cervix (HeLa) cells [125].More-
over, a recent clinical trial showed that EGCG may improve
the prognostic of breast cancer patients under radiotherapy
[119].
Melatonin is one of the most studied antioxidants in
recent years, both in in vitro and in vivo assays. As it was
hypothesized by Vijayalaxmi et al. [175], melatonin may slow
the saturation of repair enzymes. This fact would lead to
repairing the damage caused by oxidative stress and also
would allow the use of higher doses of radiation in the
treatment,makingmelatonin an ideal protective agent during
radiotherapy. Although, in most studies, melatonin has been
used at very high doses (it is not toxic up to 250mg/kg), it
was found that its administration at low doses in mice, over a
period of time (e.g., 0.1mg/kg/day for 15 days before receiving
radiation), appeared to be quite effective, so that the suitable
dose of melatonin for humans in radiotherapy treatments
is an issue that has to be investigated in more depth [126]
(Table 2(b)).
As for chemotherapy, there are numerous agents that
induce cell death by oxidative stress either directly, leading
to the disruption of redox signaling and ROS scavenging,
or indirectly by reducing intracellular levels of antioxidants
and deactivating the cellular defense. Numerous articles have
reported on many chemotherapeutic agents whose effects
involve the induction of oxidative stress. Some of them are
new molecules as Meroxest, a synthetic merosesquiterpene
derivative of the trans-communic acid, plentiful in Cupressus
sempervirens [176], or Jadomycin, which is synthesized by
the bacteria Streptomyces venezuelae [177]. Other compounds
are part of the current therapeutic repertoire, like oxaliplatin
[178], bleomycin [179], gemcitabine [180, 181], cyclophos-
phamide [182], celecoxib [183], capecitabine [184, 185], borte-
zomib (a proteasome inhibitor, approved for the treatment
of multiple myeloma) [186, 187], and arsenic trioxide (ATO).
ATO, which is used in the treatment of acute promyelocytic
leukemia (APL), can produce a loss of permeability of the
outer mitochondrial membrane and impair the function of
the respiratory chain, leading to an increase in superoxide
anion [188–191]. However, many of the agents that induce
oxidative stress have hardly any studies about the interaction
between their antineoplastic activity and antioxidants.
Then, we present the information about various antitu-
mor drugs which have been selected according to their utility,
therapeutic efficacy, and involvement in studies that were
focused on the evaluation of the interactionwith antioxidants
during chemotherapy.
Anthracyclines are antitumor antibiotics commonly used
in chemotherapy. They have been linked to the generation
of oxidative stress and increased ROS levels and could act as
mediators of apoptosis by the activation of caspases 3 and 9
[192–194]. Doxorubicin (Adriamycin) is a widely anthracy-
cline used in the treatment of various cancers, including solid
breast and prostate tumors. It exerts its antitumor activity
by inhibiting topoisomerase II and generating ROS, hereby
producing DNA damage and cell death by apoptosis [195,
196]. This increasing of ROS seems to play an important role
in the cardiotoxicity caused by doxorubicin [197].
There are in vitro studies which have indicated that the
administration of antioxidants could counteract the toxicity
of this drug in cardiomyoblasts, although other studies have
shown different results. For example, vitamin E could exert a
cardioprotective effect but only against chronic cardiotoxic-
ity, not against the development of chronic cardiomyopathy
[198]. Recently,Wu et al. were able to reduce apoptosis in car-
diomyocytes and also the oxidative stress in a model of heart
failure in Japanese white rabbits, using intravenous injections
of doxorubicin after being treated with NAC [127]. In another
experimental trial, it was intended to evaluate the influence
of vitamin C on the cytotoxicity caused by antineoplastic
agents, such as doxorubicin. As a result, it was observed
that when the level of vitamin C was increased, there was
Oxidative Medicine and Cellular Longevity 9
Table 2: Antioxidants and antitumor therapy: (a) clinical evidence, (b) preclinical evidence.
(a)
Clinical evidence
Treatment Disease Results Reference
High dose of vitamins C and E + radiotherapy HNSCC Improve adverse effects but decreaseeffectiveness of the treatment [116, 117]
Normal dose of vitamins C, E and 𝛽-carotene +
cisplatin + radiation Cervical cancer
Decrease oxidative damage, increased
muscle strength, and less fatigue [118]
EGCG + radiotherapy Breast cancer Decrease the levels of angiogenic factorsand HGF [119]
Uncaria tomentosa + FAC Breast cancer Decrease the adverse effects withoutinterfering with the efficacy of treatment [120]
NAC and vitamin E + vincristine, doxorubicin,
cytosine arabinoside, cyclophosphamide, and
6-mercaptopurine + radiation
ALL
Decrease the incidence of toxic hepatitis
Decrease the requirement of blood and
platelet transfusions during treatment
[121]
Melatonin + cisplatin plus etoposide or cisplatin
plus gemcitabine NSCLC Increase the rate of tumor regression and
greater two-year survival rate [122]Melatonin + oxaliplatin and 5-FU Gastrointestinal cancer
Melatonin in combination with chemotherapy Advanced NSCLC Decrease the side effects with no betterrates of survival [123]
HNSCC: head and neck squamous cell carcinoma; ALL: acute lymphoblastic leukemia; NSCLC: non-small-cell lung carcinoma.
(b)
Preclinical evidence
Treatment Experimental model Results Reference
Curcumin + radiotherapy SCC1, SCC-9, A431, and KB of HNSCC Increase the antitumor effect of radiation [124]
EGCG + radiotherapy
Tumor cervical cells (HeLa), multiple
myeloma (IM-9), and leukemic
(K-562)
Decrease cell proliferation
Increase apoptosis and necrosis [125]
Melatonin + radiotherapy CD2-F1 mice Increase the survival of animals [126]
NAC + doxorubicin Model of heart failure in Japanesewhite rabbits Decrease apoptosis in cardiomyocytes [127]
Vitamin C + doxorubicin
Cell lines of chronic myelogenous
leukemia (K562) and lymphoma (RL) Increase the resistance to treatment [128]
Mice with RL cell xenografts Larger tumors in mice
Suppression of Prdx + doxorubicin MCF-7 human breast tumor cells Increase the apoptotic effect of the drug [129]
ECGC + doxorubicin Colorectal tumor cells(BEL-7404/DOX)
Increase cell death and the sensitivity to
the drug [130]
Resveratrol + paclitaxel Human breast tumor cells Decrease the antitumor action of the drug [131]
Nitroxide + docetaxel or
doxorubicin
Mice with breast tumor cells
xenografts
Decrease the side effects without
interfering with the efficacy of treatment [132]
Quercetin + cisplatin or 5-FU,
taxol, or pirarubicin
Ovarian tumor cells (C13∗ and
SKOV3)
High concentrations of quercetin:
proapoptotic effect
Low concentrations of quercetin:
decrease the damage caused by ROS
[133]
Quercetin at low doses + cisplatin,
5-FU, taxol, or pirarubicin
Athymic nude mice with
ovarian tumor cells (C13∗) xenografts Inefficiency in the treatment [133]
High dose of vitamins A, E and
selenium + cisplatin
Tumor cells of colon
(COLO-205-GFP) induced in mice
Significant lower growth of tumors
compared to the control tumors [134]
Curcumin + cisplatin Liver tumor cells (HA22T/VGH) Increase the cytotoxic effect of the drug [135]
HNSCC tumor cells (CAL27, UMSCC) [136]
NAC before or up to 1 hour after
the drug + cisplatin
Human ovarian carcinoma
cells(SKOV3), human SCLC tumor
cells (B.5 LX-1), human glioblastoma
cells (U87), and rat Rat1 fibroblasts
Blocks the proapoptotic effect of the drug [137]
NAC up to 4 hours after drug +
cisplatin Long-Evans rats
Otoprotective without interfering with
the efficacy of treatment [138]
Lycopene + cisplatin Adult male Sprague-Dawley rats Decrease the renal toxicity withoutinterfering with the efficacy of treatment [139]
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a greater resistance to treatment in two cell lines of chronic
myelogenous leukemia (K562) and lymphoma (RL). It also
occurred in mice with RL cell xenografts. Moreover, after 32
days of treatment, when vitamin C was given to mice 2 hours
before being treated with doxorubicin, the tumors became
almost four times larger than the tumors of mice treated with
just doxorubicin. So, they concluded that vitamin C seemed
to interfere with the cytotoxic effect of doxorubicin [128].
In other cases, antioxidant supplements have shown
positive effects, without affecting the effectiveness of treat-
ment. The combination of 5-fluorouracil, doxorubicin, and
cyclophosphamide (FAC) appears to involve a decrease in
antioxidant levels, as a result of the lipid peroxidation
produced in the cell membrane [199]. In a clinical trial
conducted with patients treated with FAC who were in
stage II of invasive ductal carcinoma of breast, the aim
was to test the effectiveness of Uncaria tomentosa. It was
observed that the patients who received chemotherapy along
with 30mg/day of the extract of the plant experienced a
decrease of the adverse effects from chemotherapy such
as neutropenia, without affecting the effectiveness of drugs
[120]. Similarly, tannins (a type of polyphenols) administered
during the treatment with doxorubicin showed their capacity
of lowering the cardiotoxicity caused by the drug, without
reducing its antitumor efficacy.
The ability of EGCG as an adjuvant in chemotherapy
has also been investigated both in vitro and in vivo [125].
This catechin exerts synergistic effects with doxorubicin in
chemoresistant models of hepatocellular carcinoma (HCC).
In addition, in vivo studies showed that mice receiving
EGCG with doxorubicin experienced a lower growth rate
of liver tumors than mice that received only doxorubicin
[130]. Similarly, other trials evaluated the combination of
EGCGwith other drugs such as 5-FU and cisplatin, and their
conclusions also suggest the great potential of this catechin as
adjuvant in anticancer therapy [200, 201].
A very important topic in antitumor therapy based on
doxorubicin is the development of drug resistance. In this
regard, the relationship between this resistance and the
presence of endogenous antioxidants was recently described.
So,McDonald et al.managed to demonstrate the involvement
of peroxiredoxins (Prdx) in the doxorubicin resistance of
MCF-7 breast tumor cells. Prdx are a family of six proteins
expressed in mammals which are thiol-specific antioxidants.
This trial showed that MCF-7 had elevated levels of Prdx
compared to nontumor cells MCF-10A, and the levels of
these proteins in line MCF-7 resistant to doxorubicin were
higher. This study also reported that the suppression of the
expression of four of these six Prdx led to increasing the
apoptotic effect of doxorubicin [129].
Taxanes are anticancer cytotoxics that include paclitaxel,
which is a natural antitumor drug used to treat various
types of tumors. Numerous studies have indicated that it





. A recent study reported a
reduction of glutathione levels in blood samples collected
from patients treated with Paclitaxel, which implies that
there was a decrease of the antioxidant potential of cells
[202]. In vitro studies also point in the same direction. T47D
and MDA-MB231 breast tumor cells, treated with scavengers
(NAC, catalase, or SOD), were able tomaintain their viability.
It was discovered how another agent, such as 2-deoxy-D-
glucose (a competitive inhibitor of glycolysis), was able to
promote a prooxidant effect of paclitaxel [203]. In other trials,
it was shown that the administration of resveratrol, during the
treatment with paclitaxel, decreased its antineoplastic action
against breast tumor cells both in vitro and in vivo [131].
Docetaxel (Taxotere) is a derivative of paclitaxel that
is often used as a first-line drug to treat prostate cancer
and other types of tumors. According to some research, its
way of inducing cell death would be due to microtubule
depolymerisation [204]. It has also been reported that this
drug is able to induce oxidative stress by activating caspase
3 [205, 206]. Recently, the prooxidant effect of docetaxel on
breast tumor cells (MDA-231 andMCF-7) was demonstrated,
which could be enhanced with the addition of C6 ceramide
(a cell-permeable-short-chain ceramide), increasing the drug
toxicity [207].
Attending to reduce the side effects of this drug, a
reduction of oxidative stress in blood levels of mice with
breast tumor cells xenografts was found, due to the sup-
plementation of a nitroxide (3-carbamoylpyrroline nitroxyl
derivative pirolin) when they were treated with docetaxel and
doxorubicin. It also was found that this compound did not
interfere with the antitumor activity of these drugs [132].
Cisplatin was the first heavy metal used for treating
cancer and it has been widely used to treat solid tumors of
lung, ovary, testes, and lymphoma, among others [208, 209].
Its mechanism of action involves the generation of an intense
oxidative stress but also causes numerous side effects due to
their toxicity [133, 210]. Its mechanism of action is associated
with the expression of p53 (tumor suppressor gene), anti-
apoptotic Bax proteins, p21 protein (cell cycle regulator), and
the cleavage of PARP and caspases 3 and 9 [137]. After an
extensive review, it has come to our attention that there is a
large literature focused on the study of interactions between
treatment with cisplatin and antioxidant supplementation, so
this fact may be a reflection of the importance of this drug
in the treatment of cancer. Here we report some of the most
clarifying studies about this drug.
The role of quercetin is remarkable, since it has been
reported in several studies that it seemed to act as an
adjuvant in the treatment with cisplatin. In a recent study on
the treatment with cisplatin in ovarian tumor cells (C13∗ and
SKOV3), it was found that high concentrations of quercetin
(40 𝜇M–100 𝜇M) appeared to have a proapoptotic effect,
while low concentrations (5𝜇M–30 𝜇M) seemed to reduce
the damage caused by ROS.This reduction of the damage was
due to the increase of SOD, and therefore the antineoplastic
effect of cisplatin was attenuated. Similarly, the interaction
of quercetin with commonly used drugs in the treatment of
ovarian cancer (5-FU, taxol, and pirarubicin) was analyzed
and the results were alike. Moreover, in vivo studies using
athymic nude mice with C13∗ cells xenografts showed
that low doses of quercetin could cause inefficiency in the
treatment with cisplatin, 5-FU, taxol, or pirarubicin [133].
Other studies have reported that some antioxidants help
to slow the progression of tumor cells. It was discovered
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that tumor cells of colon (COLO-205-GFP) induced in mice
that were treated with cisplatin and received high-dose
supplements of vitamins A, E and selenium (5 times higher
than the standard diet) along with fish oil experienced a
significant lower growth compared to the control tumors
[134]. However, the mechanism responsible for this effect has
not been explained.
An interesting clinical trial evaluated the effect of vitamin
supplementation on the quality of life of patients with cervical
cancer, at different stages of the disease and undergoing treat-
mentwith cisplatin. In this case, chemotherapywas combined
with radiation and cisplatin, and parallely patients took vita-
mins C, E and 𝛽-carotene. Most of patients, aged between 29
and 73, displayed lower antioxidant levels than recommended
(except for vitamin C and zinc) in the pretrial serum analysis.
The results showed that women who took supplements
during the treatment had less oxidative damage (lower con-
centration of free carbonyls in serum), their muscle strength
was increased, and they showed less fatigue than women who
did not take them. It is noteworthy that, in this study, the dose
of supplement contained the recommended daily doses, not
like other studies in which doses were much higher [118].
Curcumin is another antioxidant that, in addition to its
mentioned radiosensitizer potential, has also been investi-
gated in the role of adjuvant therapy with cisplatin. In an in
vitro assay performed with liver tumor cells HA22T/VGH, it
was reported that curcumin enhanced the cytotoxic activity
of the drug [135, 211] and so it did against HNSCC tumor cells
(CAL27 and UMSCC lines) both in vitro and in vivo [136].
There have beennumerous studies focused on the study of
the effects of NAC during the treatment with cisplatin. It has
been reported that the administration of NAC can reverse the
cytotoxicity and the proapoptotic effects exerted by cisplatin,
in human SKOV3 ovarian carcinoma cells, human B.5 LX-1
SCLC, humanU87 glioblastoma cells, and rat Rat1 fibroblasts,
reaching values of up to 99% reduction in its efficacy. Inter-
estingly, they found that the proapoptotic effect of cisplatin
was blocked by NAC if it was administered before or up to 1
hour later than the drug. In case of adding the antioxidant 8
hours after the cisplatin applying, no changes occurred in the
proapoptotic effects [137]. Similarly, thanks to other studies
in vivo, it has been found that NAC can be otoprotective
when it is administered up to 4 hours after cisplatin [138].
It was also found that the best route of administration of
NAC, in order to improve protection against the renal damage
caused by cisplatin, is the intra-arterial (compared to the oral,
intravenous, and intraperitoneal routes) [212]. According to
these trials, it appears that both the timing and the route of
administration of the antioxidantmay be important factors to
provide some nutritional recommendations associated with
cancer treatment. In addition to NAC, other antioxidants
have been evaluated to reduce the toxicity of cisplatin, such as
lycopene, which has demonstrated its capability of reducing
the renal toxicity induced by this drug [139].
The effect of NAC has also been evaluated in patients
treated with combinations of chemotherapy agents plus
radiotherapy. A clinical trial, in which 40 children with acute
lymphoblastic leukemia (ALL) took part, was intended to
assess whether the intake of NAC and vitamin E (400 IU/day)
orally would counteract the high toxicity from chemotherapy
(vincristine, doxorubicin, cytosine arabinoside, cyclophos-
phamide, and 6-mercaptopurine) and the prophylactic cra-
nial irradiation during the first two months of treatment.
After analyzing blood levels of GPx, malondialdehyde
(MDA), tumor necrosis factor-𝛼 (TNF-𝛼), and liver enzymes,
the results indicated that children who received antioxidants
showed lower incidence of toxic hepatitis and less probabili-
ties of requirement of blood and platelet transfusions during
treatment [121].
As mentioned earlier, melatonin has a great antioxidant
capacity through different mechanisms of action. Therefore,
we have referred to its role as adjuvant in chemotherapy
to treat various cancers. In a clinical trial conducted by
Lissoni, the effect of administration of 20mg/day of oral
melatonin was evaluated in patients with NSCLC treated
with cisplatin plus etoposide or cisplatin plus gemcitabine,
or gastrointestinal cancer treated with oxaliplatin and 5-FU.
In both cases, patients who received melatonin had a higher
rate of tumor regression and a greater two-year survival rate
[122]. And more recently, Sookprasert et al. revealed the
results of the MIRCIT trial, which concluded that advanced
NSCLC patients receiving melatonin in combination with
chemotherapy did not get better levels of survival, though
the side effects were fewer [123]. It would be necessary to
continue further studies to clarify the role of melatonin
and to be able to compare these two clinical trials. This
would allow us to establish the similarities and differences
between the advanced and nonadvanced NSCLC patient,
their appropriate treatment, and their basal serum levels of
antioxidants, in order to compare the results of both studies.
8. Conclusions and Future Perspectives
Considering all the results exposed above, we conclude that
antioxidant intake seems to influence the effectiveness of
antitumor therapy and its adverse effects.However, we believe
that at the moment it cannot be possible to give a general
recommendation on whether or not to take antioxidants
during treatment. This is because the final effect will depend
on the type of cancer, the mechanism of action of the drug or
drugs used in the treatment, and the type of antioxidants.
More studies are needed to clarify the results of the clini-
cal trials, which sometimes are contradictory to each other. It
is necessary to define the most appropriate patient profiles to
adopt a nutritional regimen that could contribute to a better
result of antitumor therapy. Aspects such as disease stage,
treatment resistance, and previous cycles of chemotherapy
and/or radiotherapy may be important factors in this regard.
The variable influence of antioxidants on antitumor ther-
apy can be clearly illustrated considering lung cancer patients,
for whom the intake of supplements with high doses of 𝛽-
carotene is harmful, especially in smokers, and it has been
correlated with a worse prognosis. However, mineral antiox-
idants seem to produce a beneficial effect on prostate cancer.
Thus, the intake of selenium togetherwith vitaminE, at physi-
ologic doses and for a long period of time, appears to decrease
the incidence of the disease. Similarly, zinc appears to inhibit
the proliferation of prostate tumor cells. Paradoxically, zinc
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must be ingested through the diet or as a supplement at
physiologic doses (below 100mg/day), because higher doses
can produce the opposite effect. Furthermore, the admin-
istration of different antioxidants with the same antitumor
drug can also produce very diverse effects. Thus, the intake
of vitamin C supplements during the doxorubicin treatment
has been associated with an acceleration of the malignant
process, whereas if some polyphenols are administered, such
as tannins, the systemic toxic effects of the drug could be
reduced, without interfering with the efficacy of doxorubicin.
Some clinical studies have shown that certain antioxi-
dants could have synergy with some drugs, enhancing its
activity. In this regard, NAC, melatonin, and some flavonoids
appear to be the most promising antioxidant candidates for
cancer therapies. Since the antioxidant environment has been
associated with a reduction of the activity of some drugs, it
would be very interesting to conduct new trials, in which
one of these antioxidants is administered to patients under
nutritional restriction of antioxidants. The antioxidant status
of cells has been correlated with the resistance against drugs
that exert their antitumor effects through the induction of
oxidative stress. Therefore, it would be interesting to evaluate
the basal antioxidant status of the patients, by determining
serum levels of antioxidants. This study could serve in the
future to adjust the doses of exogenous antioxidants. The
moment of administration of the exogenous antioxidants
seems to be another important factor. In fact, and according
to the results of the studies reviewed in this paper, it could
be possible that dietary recommendations to patients should
not be needed to be followed long time after receiving the
drug dose. This is due to the fact that the interaction of
antioxidant and drugs seems to disappear a few hours after
their administration. Similarly, other important topics are the
route of administration and the dosage of antioxidants, since
they may affect the effectiveness of the treatment.
It is also important to deepen the understanding of
the biochemistry of endogenous antioxidants which are
responsible for the failure of some treatments, as in the
case of Prdx proteins, which reduce the therapeutic efficacy
of doxorubicin. This study would allow the discovery and
development of specific inhibitors of such proteins and
therefore improve the treatments. In fact, there are already
specific inhibitors of SOD and other endogenous enzymes,
such asDDT (sodiumdiethyldithiocarbamate) or ellagic acid,
which are being studied to be used to enhance the effect of
different cytotoxic agents.
Although it is possible to find in the literature numerous
articles that discuss the interaction between cancer and
antioxidant therapy, there are many drugs for which this
kind of studies has not been performed yet. Future research
would be helpful to establish concrete recommendations
for patients, in order to improve the response to cancer
treatment. In our opinion, it is necessary to define specific
guidelines for each type of patient, which have to take
into account the following: type of cancer; molecular
subtype; stage of the disease; therapy, considering the type of
drugs, their mechanisms of action, and the cycles; previous
treatment; basal antioxidant status; the type of antioxidants
that appear to produce a better response with the selected
treatment; route of administration; dosage; and the diet of
the patient and habits, with the purpose of correcting the
antioxidant intake if some restriction or supplementation is
necessary. The main problems related to antioxidants clinical
trials may be to define homogeneous groups of patients
regarding the histopathological and molecular classification
and treatment and to control the pool of serum antioxidant
that results from the intake of supplements and habits (diet,
alcohol, smoking, etc.). Therefore, these clinical trials should
be addressed by multidisciplinary teams comprising at least
oncologists and nutritionists.
We believe that nutritional recommendations about
exogenous antioxidant supplementation or restriction, as
appropriate, carried out in parallel to cancer treatment, could
contribute to improving its efficiency.
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